Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Non-cash Items: 2022-2024

Historic Non-cash Items for Silence Therapeutics (SLN) over the last 3 years, with Dec 2024 value amounting to $29.1 million.

  • Silence Therapeutics' Non-cash Items was N/A to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year change of. This contributed to the annual value of $29.1 million for FY2024, which is 868.60% up from last year.
  • As of FY2024, Silence Therapeutics' Non-cash Items stood at $29.1 million, which was up 868.60% from $3.0 million recorded in FY2023.
  • Silence Therapeutics' Non-cash Items' 5-year high stood at $29.1 million during FY2024, with a 5-year trough of $2.3 million in FY2022.
  • Moreover, its 3-year median value for Non-cash Items was $3.0 million (2023), whereas its average is $11.5 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first decreased by 28.48% in 2023, then surged by 868.60% in 2024.
  • Silence Therapeutics' Non-cash Items (MRY) stood at $2.3 million in 2022, then increased by 28.48% to $3.0 million in 2023, then surged by 868.60% to $29.1 million in 2024.
  • Its Non-cash Items was $29.1 million in FY2024, compared to $3.0 million in FY2023 and $2.3 million in FY2022.